TORONTO and HAIFA, Israel, Aug. 21, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (“NurExone” or the “Company”) (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) is pleased to announce that it will hold its annual general and special meeting of shareholders on September 15, 2026 (the “Meeting”) to seek shareholder approval for a special resolution authorizing the board of directors of the Company (the “Board”) to effect a consolidation of the Company’s issued and outstanding common shares (the “Shares”) on the basis of up to thirty (30) pre-consolidation Shares for one (1) post-consolidation Share (the “Consolidation”). If the Consolidation resolution is approved by shareholders, the Board will be authorized, in its sole discretion, to implement the Consolidation within 36 months following shareholder approval, subject to acceptance of the TSX Venture Exchange (“TSXV”) and receipt of all other required approvals. The exact timing and final ratio will be determined by the Board, which may elect not to proceed with the Consolidation. The Board believes that providing flexibility on the timing and ratio allows the Company to account for market conditions, trading performance, and applicable listing requirements prior to implementation. To be approved, the Consolidation resolution must receive the affirmative vote of not less than 66⅔% of the votes cast by shareholders at the Meeting.
The Meeting will be held at 2:00 p.m. Toronto time on September 15, 2026 at the Company’s head office at Suite 801, 1 Adelaide Street East, Toronto, Ontario. Shareholders should follow the voting instructions in the Meeting materials, including the applicable proxy and voting instruction deadlines.